探索花粉在治疗良性前列腺增生症中的作用和机制
Jun Mu1, Junsheng Wu1, Linrui Duan1
1Biomedicine Key Laboratory, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Heliyon
|November 30, 2023
概括
梨花花粉 (PP) 通过减少前列腺大小和改善组织结构,有效治疗良性前列腺增生症 (BPH). 它的机制涉及调节PI3K-AKT通路,为BPH治疗提供科学基础.
科学领域:
- 草药是一种草药.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 梨花花粉 (PP) 在中国传统医学中用于治疗良性前列腺增生 (BPH).
- 在治疗BPH时PP的有效性背后的分子机制尚不清楚.
- 了解这些机制对于验证其治疗用途至关重要.
研究的目的:
- 通过实验证实PP对BPH的治疗作用.
- 通过网络药理学阐明PP在BPH治疗中的分子机制.
主要方法:
- 建立了BPH的动物模型,并用PP处理.
- 使用了网络药理学,包括化合物和标识,PPI网络分析和分子对接.
- 进行了基因本体学 (GO) 和基因和基因组学 (KEGG) 京都百科全书的途径分析.
- 西方斑被用来验证关键蛋白质表达.
主要成果:
- PP治疗减少了前列腺体积,前列腺指数以及 (T),二 (DHT) 和雌激素 (E2) 的血清水平.
- 在BPH模型动物中,PP改善了前列腺组织结构.
- 网络药理学确定了关键化合物和点,PI3K-AKT通路被强调为关键.
- 西方涂抹证实了PP对PI3K和AKT激活的调节.
结论:
- 在动物模型中,PP显示出针对BPH的显著治疗效果.
- 该研究初步揭示了PP的作用机制涉及调节PI3K-AKT信号通路.
- 这些发现为PP在BPH管理和进一步研究中的使用提供了科学基础.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:24Antiasthma Drugs: Methylxanthines
238
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
238
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
845
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
845
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174